milliporesigma videos

31. Targeting The Fast Lane With Optimized Viral Detection 4/6/2023

    Discover a groundbreaking method that allows you to accelerate viral detection by combining the broad range of NGS with the sensitivity of PCR.

32. A Dedicated Team To Safely Store Your Cell And Virus Banks 2/27/2023

    The safety of your cell and virus banks must be your top priority. Learn about a team dedicated to the safety of your material along with their related services.

33. Storing Your Banks With Ease And Confidence 2/17/2023

    Discover a biorepository that will fulfill your need of long-term and short-term storage. You can never be too careful with your cell or virus banks. Explore three global sites that will ensure the safety of your bank.

34. The Journey To Safety Through Viral Clearance 12/1/2022

    Discover a simple yet powerful solution for getting viral clearance studies done safely, thoroughly, efficiently, and on your timelines. Learn how to free your teams and trust your project.

35. The ICH Q5A Revision, Its New Scope And Guidance 12/1/2022

    Learn about the ICH Q5A revision addressing viral safety of biotechnology products derived from cell lines of human or animal origin that was recently published for public comment.

36. ICH Q7 Good Manufacturing Practice Guide For Active Pharmaceutical Ingredients 6/7/2022

    The ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients is the most commonly referenced quality guideline in pharmaceutical product and contains five segments. Watch the video to learn more.

37. Partner With A CDMO For Your Biologic Commercial-Scale Manufacturing 3/18/2022

    Discover how our full-service biologics CDMO can help you navigate the journey from clinical to commercial drug substance manufacturing and provide tailored guidance and solutions.

38. Combining Expertise With Best-In-Class Technology 10/20/2021

    Members of the MilliporeSigma leadership team reflect on the longstanding experience of our BioReliance® viral vector manufacturing facilities. Our legacy experience, alongside our brand new facility and latest industry innovations, ensure we are a preferred partner to pioneer the path to cures.

39. How MilliporeSigma Promotes Quality And Risk Reduction 10/20/2021

    Learn how MilliporeSigma’s new facility was built with quality and risk reduction at the top of mind and its experts have the experience to support large-scale programs through commercialization.

40. MilliporeSigma Large Scale Capabilities Tour 10/20/2021

    A detailed look at MilliporeSigma’s new BioReliance® viral vector manufacturing facility and how we have employed the latest innovations and quality systems to deliver best-in-class gene therapy services.